BPC-157

No human study has measured how quickly BPC-157 works. On peptide forums, some users describe changes within 1-2 weeks and more over 4-8 weeks, while others report no benefit after 3-6 weeks. These are self-reports, and the timeline people describe varies with the type and severity of the injury.

Many users inject near the injury, and others inject under the skin of the abdomen, but no human study has compared the two. The animal studies behind most BPC-157 claims mostly used systemic routes (intraperitoneal, intramuscular, intravenous or oral) and still reported effects in tendon and muscle. The case for local injection rests on user reports, not trial data.

Rodent studies describe BPC-157 as stable in gastric juice, which is the basis for oral forms. No published human study has measured its oral bioavailability: an oral Phase 1 trial (PCO-02) was registered, but as of October 2026 its status is listed as unknown and no results have been posted. In vendor and community guidance, injectable forms are generally considered more effective for research purposes, and oral forms are usually described for gut-related research. Neither claim has been tested in people.

Long-term safety in humans is unknown. A 2025 systematic review found no clinical safety data, and the longest animal safety studies it included lasted 6 weeks (rats and dogs, with no organ damage reported). Three small human pilots with 30 people in total reported no adverse effects, but none was designed to detect uncommon or delayed problems. Reviewers have raised a theoretical concern about its effect on blood-vessel growth, although some animal data suggest it may suppress tumor-related blood-vessel signaling. Long-term human studies are lacking, and research should be conducted responsibly.